According to World Health Organization data, diabetes mellitus (DM) affects 425 million people in the world today, most of them from low- and middle-income countries and social segments. About a third of diabetic patients have diabetic retinopathy of any stage (DR), and 7% have proliferative diabetic retinopathy (PDR). Even in the ETDRS study, which included cases with timely laser photocoagulation, the 5-year cumulative incidence of vitrectomy was found to be 5.3%. The incidence of PDR and associated blindness has decreased owing to the improvements in diabetes monitoring and treatment. Also, the application of anti-vascular endothelial growth factors (anti-VEGF) and refinement of surgical techniques have greatly improved the management of diabetic eye complications.